Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO
Journal of Cystic Fibrosis · 2026
DOI: 10.1016/j.jcf.2026.01.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Meghan Shirley Bezerra und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: shirleybem@chop.edu. Hauptthemen laut MEDLINE: Aminophenols, Benzodioxoles, Bone Density, Cystic Fibrosis. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cystic Fibrosis Foundation, National Center for Advancing Translational Sciences, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Low bone mineral density (BMD) and increased fracture risk are common in individuals with cystic fibrosis (CF). The extent to which the CF transmembrane conductance regulator (CFTR) modulator elexacaftor-tezacaftor-ivacaftor (ETI) benefits BMD was a focus of the endocrine sub-study of PROMISE, a multicenter observational study of clinically prescribed ETI. We examined changes in whole-body (WB), lumbar spine (LS), total hip (TH), and femoral neck (FN) areal BMD (aBMD, g/cm2) in the 24-30 months (mos) following ETI initiation. METHODS: Participants had CF, ≥1 F508del mutation, and were aged ≥12 years (y). Dual-energy X-ray absorptiometry (DXA) scans of the WB, LS, TH, and FN were collected before and following 12-18 mos and 24-30 mos of ETI therapy. Changes in aBMD Z-scores (aBMDZ) were examined with longitudinal mixed effects models. RESULTS: Baseline aBMDZ was below-average at all skeletal sites in youth and adults (aBMDZ -0.11). CONCLUSIONS: Youth aBMDZ was lower at multiple skeletal sites 12-18 mos after ETI initiation, and these changes persisted at 24-30 mos. Adult aBMDZ generally remained unchanged.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: shirleybem@chop.edu.
- Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, US…
- Department of Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
- Department of Medicine, University of North Carolina at Chapel Hill, NC, USA.
- Jacobs School of Medicine and Biomedical Sciences of the University of Buffalo, NY, USA.
Förderung
- Cystic Fibrosis Foundation
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Shirley Bezerra, M., Zemel, B. S., Gallop, R. J., Walega, R., Donaldson, S. H., Frederick, C. A., Freedman, S. D., Gelfond, D., Hoffman, L. R., Narkewicz, M. R., Rowe, S. M., Sagel, S. D., Schwarzenberg, S. J., Solomon, G. M., Chan, C. L., Kelly, A., & PROMISE Endocrine Sub-study Group (2026). Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2026.01.006
Vancouver
Shirley Bezerra M, Zemel BS, Gallop RJ, Walega R, Donaldson SH, Frederick CA, et al. Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2026.01.006
BibTeX
@article{ShirleyBezerra2026,
author = {Shirley Bezerra, Meghan and Zemel, Babette S and Gallop, Robert J and Walega, Rachel and Donaldson, Scott H and Frederick, Carla A and Freedman, Steven D and Gelfond, Daniel and Hoffman, Lucas R and Narkewicz, Michael R and Rowe, Steven M and Sagel, Scott D and Schwarzenberg, Sarah Jane and Solomon, George M and Chan, Christine L and Kelly, Andrea and PROMISE Endocrine Sub-study Group, PROMISE Endocrine Sub-study Group},
title = {Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO},
journal = {Journal of Cystic Fibrosis},
year = {2026},
doi = {10.1016/j.jcf.2026.01.006}
}
EUVIMED